If you enjoy this content, please share it with a colleague
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that its Accipio intracranial hemorrhage (ICH) and stroke software will be integrated on Philips’ computed tomography (CT) systems. The integration of Accipio’s AI-powered solutions into Philips CT systems will support the detection of ICH to augment caregivers in identifying and prioritizing patients suffering from stroke, traumatic brain injury, head trauma and other life-threatening conditions.
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that Accipio Ax will begin shipping in August and will be available as the second part of the Accipio ICH Platform. Accipio Ax will provide new tools to support clinical assessment of intracranial hemorrhage (ICH). Radiology departments, emergency room and neuroradiology teams across the U.S. and the EU will soon be able to access a comprehensive solution for ICH triage through workflow prioritization and slice-level preview. Accipio Ax includes the exclusive Accipio Ax SliceMap, an integrated view which guides clinicians rapidly to computed tomography (CT) slices with suspected ICH without leaving their picture archiving and communication system (PACS) viewer.
MaxQ AI and GE Healthcare announced that MaxQ's Accipio artificial intelligence (AI) platform will now be a part of GE Healthcare's Computed Tomography (CT) Smart Subscription offering. GE Healthcare's Smart Subscription provides customers with continuous access to the latest imaging software updates, through an available automatic download to their CT scanners from the cloud. As a Smart Subscription offering, hospitals with GE Healthcare CTs can easily and seamlessly integrate MaxQ's Accipio platform, from which Accipio Ix intracranial hemorrhage (ICH) detection software is now available.
Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement to integrate MaxQ’s artificial intelligence (AI) software with Samsung NeuroLogica’s medical imaging hardware in the United States and European Union acute care marketplace. As part of this agreement, Samsung NeuroLogica will be able enhance its offerings with MaxQ’s Accipio Ix, part of MaxQ’s Accipio Insight intracranial hemorrhage platform, which supports acute care physicians by identifying patients with suspected intracranial hemorrhage, and prioritizing those patients using adult non-contrast head computed tomography (CT) imaging.
The FDA cleared the MaxQ AI Accipio Ix intracranial hemorrhage (ICH) detection software in November 2018. Here it is ...
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The clearance paves the way for healthcare providers and physicians in acute care settings to have access to this artificial intelligence (AI) software designed to aid in prioritizing the clinical assessment of adult non-contrast head computed tomography (CT) cases that exhibit indications of intracranial hemorrhage (ICH), commonly known as a brain bleed.